Events
-
2025/06/10 Correctseq
CorrectSequence Therapeutics to Participate in EHA2025 Congress
June 10, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation at the EHA2025 Congress, taking place June 12 – 15, 2025, in Milan, Italy.
-
2025/05/23 China Daily
China Daily | Chinese treatment cures Pakistani girl
A 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor, according to the Children's Hospital of Fudan University in Shanghai.
-
2025/05/21 SHINE
SHINE | Innovative treatment developed in China saves 4-year-old
A 4-year-old Pakistani girl with a serious blood disorder – thalassemia – has been cured by a China-developed innovative gene-editing technology, doctors at the Children's Hospital of Fudan University said on Tuesday.
-
2025/03/27 Correctseq
Precise and Efficient RNA Editing by Cleaving ADAR Inhibitor
Recently, a collaborative team led by Professor Chen Jia from the School of Life Science and Technology (SLST) at ShanghaiTech University and Professor Yang Li at Fudan University published a study titled “Specific and Efficient RNA A-to-I Editing through Cleavage of an ADAR Inhibitor”in Nature Biotechnology.
-
2025/03/27 Correctseq
An Efficient and Precise Mitochondrial Adenine Base Editor
Mitochondria, the “powerhouses” of cells, play a vital role in adenosine triphosphate (ATP) production. Mitochondria possess their own independent DNA, termed mitochondrial DNA (mtDNA), which encodes
-
2025/03/19 Correctseq
CorrectSequence Therapeutics’ CS-101 Successfully Treats Malaysian β-Thalassemia Patient
CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced its self-developed base editing therapy, CS-101, has achieved another major milestone in the treatment of β-thalassemia. In collaboration with the First Affiliated Hospital of Guangxi Medical University, CS-101 has successfully treated the second overseas patient—a Malaysian individual with transfusion-dependent β-thalassemia. This milestone follows the first cure of a β-thalassemia overseas patient from Laos, marking another significant global achievement for the company
-
2024/12/10 SHINE
Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder
A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.
-
2024/12/05 Correctseq
CorrectSequence Therapeutics to Participate in the 66th ASH Annual Meeting and Exposition
Dec 5, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announc